AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31369675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear treatment (CH) started at age 9.5 years (Late Group - LG)
Number of subjects: 67
Study 28894768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid + 3% hypertonic solution
Number of subjects: 264
Study 28894768 — intervention group
Group type: COMPARATOR
Intervention: 3% hypertonic solution
Number of subjects: 264
Study 26112284 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cycling exercise training (set at 100% WRpeak with 30‐s work/30‐s rest intervals) for 12 weeks
Number of subjects: 25
Study 23993873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillographic Sleepiness Test (PST)
Number of subjects: 163
Study 23993873 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sleepiness assessment via questionnaires
Number of subjects: 163
Study 23993873 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective sleepiness assessment via PST
Number of subjects: 163
Study 23993873 — intervention group
Group type: EXPERIMENTAL
Intervention: PST reference values for lnPUI
Number of subjects: 163
Study 23993873 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of subjective sleepiness and lnPUI
Number of subjects: 163
Study 21199163 — intervention group
Group type: EXPERIMENTAL
Intervention: Early outpatient pulmonary rehabilitation programme (PRP) for 8 weeks, starting 2-3 weeks after discharge
Number of subjects: 60
Study 21199163 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 60
Study 19689221 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 828
Study 17942782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (1.5 mg/kg)
Number of subjects: 49
Study 17942782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (3.0 mg/kg)
Number of subjects: 49
Study 15337703 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery hypertension patients
Number of subjects: 17
Study 15337703 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery hypertension patients treated with prostacyclin derivatives
Number of subjects: 17
Study 15337703 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral chemoreflex deactivation with hyperoxia
Number of subjects: 17
Study 11642232 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(7) CFU of glycopeptide-resistant strains of Enterococcus faecium from chicken
Number of subjects: 18
Study 11642232 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(7) CFU of streptogramin-resistant strain of E. faecium from pig
Number of subjects: 18
Study 11642232 — intervention group
Group type: COMPARATOR
Intervention: 10(7) CFU of glycopeptide-susceptible and streptogramin-susceptible strain of E. faecium from chicken
Number of subjects: 18
Study 11263363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bletilla striata angioembolus
Number of subjects: 56
Study 11263363 — intervention group
Group type: COMPARATOR
Intervention: Conventional gelfoam embolization
Number of subjects: 56
Study 7930729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bordetella pertussis infection in children 1-3 years
Number of subjects: 239
Study 7930729 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic B. pertussis infection in preschool children
Number of subjects: 239
Study 7930729 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms compatible with clinical pertussis in schoolchildren
Number of subjects: 239
Study 7930729 — intervention group
Group type: EXPERIMENTAL
Intervention: Attack rate of laboratory-confirmed B. pertussis infection
Number of subjects: 239
Study 2850552 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily
Number of subjects: 10
Study 2850552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2850552 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10
Study 31291516 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg
Number of subjects: 1186
Study 31291516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1186
Study 29969293 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CBT + ABM
Number of subjects: 79
Study 29969293 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CBT + ACT
Number of subjects: 79
Study 29969293 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + ABM
Number of subjects: 79
Study 29969293 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + ACT
Number of subjects: 79
Study 27275618 — intervention group
Group type: EXPERIMENTAL
Intervention: Osseointegrated implants subjected to 200-cN force
Number of subjects: 0
Study 27275618 — intervention group
Group type: COMPARATOR
Intervention: Control group (implants not subjected to orthodontic force)
Number of subjects: 0
Study 24734969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive conflicts (presence of implicative dilemmas) in depressive patients
Number of subjects: 271
Study 24734969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive conflicts in depressive patients
Number of subjects: 271
Study 23021168 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water (35°‐38°C)
Number of subjects: 175
Study 23021168 — intervention group
Group type: COMPARATOR
Intervention: Cool water (20°‐23°C)
Number of subjects: 175
Study 20216276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet, physical exercise, and daily oral ingestion of 40 mg of soy isoflavones
Number of subjects: 116
Study 20216276 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet and physical exercise (control group)
Number of subjects: 116
Study 17711562 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g intravenous paracetamol
Number of subjects: 107
Study 17711562 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac
Number of subjects: 107
Study 17711562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 16311458 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression approach incorporating pre- and post-dilation lung function, age, sex, and height.
Number of subjects: 0
Study 16311458 — intervention group
Group type: COMPARATOR
Intervention: Percentage of the predicted or baseline FEV1 increase.
Number of subjects: 0
Study 12138364 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation oral contraceptive (30 microg ethinylestradiol/150 microg levonorgestrel)
Number of subjects: 86
Study 12138364 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation oral contraceptive (30 microg ethinylestradiol/150 microg desogestrel)
Number of subjects: 86
Study 12138364 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestagen-only preparation (150 microg levonorgestrel)
Number of subjects: 86
Study 12138364 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestagen-only preparation (150 microg desogestrel)
Number of subjects: 86
Study 12138364 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing OC in women with factor V Leiden
Number of subjects: 86
Study 9527763 — intervention group
Group type: COMPARATOR
Intervention: Indinavir at 1,000 mg every 8 h for 7 1/3 days with fluconazole placebo
Number of subjects: 13
Study 9527763 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole at 400 mg once daily for 8 days with indinavir placebo
Number of subjects: 13
Study 9527763 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir with fluconazole in combination
Number of subjects: 13
Study 7599543 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone at 0.30 mg/kg
Number of subjects: 30
Study 7599543 — intervention group
Group type: COMPARATOR
Intervention: Morphine at 0.30 mg/kg
Number of subjects: 30
Study 2090769 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin 2 g i.v. 15 to 20 minutes preoperatively
Number of subjects: 184
Study 2090769 — intervention group
Group type: EXPERIMENTAL
Intervention: cefotetan 2 g i.v. 15 to 20 minutes preoperatively
Number of subjects: 184
Study 359091 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate dry powder 150 microgram four times daily
Number of subjects: 20
Study 359091 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate dry powder 100 microgram four times daily
Number of subjects: 20
Study 359091 — intervention group
Group type: COMPARATOR
Intervention: Conventional aerosol 100 microgram four times daily
Number of subjects: 20
Study 30198199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fascia iliaca compartment block (FICB)
Number of subjects: 100
Study 30198199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral nerve block (FNB)
Number of subjects: 100
Study 30198199 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study 28088681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed working memory intervention
Number of subjects: 28
Study 26892074 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipe booklet and monthly reminder text messages
Number of subjects: 75
Study 26892074 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal dietary advice
Number of subjects: 75
Study 25127545 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based assessment using a low-sensitivity pregnancy test and a pictorial instruction sheet
Number of subjects: 0
Study 25127545 — intervention group
Group type: COMPARATOR
Intervention: Clinic follow-up carried out by a doctor
Number of subjects: 0
Study 22333662 — intervention group
Group type: EXPERIMENTAL
Intervention: Natamycin
Number of subjects: 120
Study 22333662 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 120
Study 22333662 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 20661550 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D2/D3 receptor agonist (pramipexole)
Number of subjects: 36
Study 20661550 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D2/D3 receptor antagonist (amisulpride)
Number of subjects: 36
Study 20661550 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study 16971058 — intervention group
Group type: EXPERIMENTAL
Intervention: 10Hz rTMS over right DLPFC
Number of subjects: 6
Study 16971058 — intervention group
Group type: COMPARATOR
Intervention: 10Hz rTMS over left DLPFC
Number of subjects: 6
Study 15831781 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 µg) injected subcutaneously at 0 hours with acetaminophen (1000 mg) ingested at -1, 0, +1, +2, and +4 hours.
Number of subjects: 40
Study 15831781 — intervention group
Group type: COMPARATOR
Intervention: Placebo injected subcutaneously at 0 hours with acetaminophen (1000 mg) ingested.
Number of subjects: 40
Study 16492988 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic-supplemented milk formula (4.5 g/L)
Number of subjects: 140
Study 16492988 — intervention group
Group type: COMPARATOR
Intervention: Control milk formula without prebiotics
Number of subjects: 140
Study 11214767 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg/day BDP via Easyhaler
Number of subjects: 15
Study 11214767 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 microg/day BDP via Easyhaler
Number of subjects: 15
Study 11214767 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 microg/day BDP via Diskhaler
Number of subjects: 15
Study 11214767 — intervention group
Group type: COMPARATOR
Intervention: Placebo via Easyhaler
Number of subjects: 15
Study 8857499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime measurements in patients with Friedreich's ataxia
Number of subjects: 19
Study 8857499 — intervention group
Group type: COMPARATOR
Intervention: Nighttime measurements in healthy age-matched subjects
Number of subjects: 19
Study 8857499 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime measurements in patients with Friedreich's ataxia
Number of subjects: 19
Study 8857499 — intervention group
Group type: COMPARATOR
Intervention: Daytime measurements in healthy age-matched subjects
Number of subjects: 19
Study 1741999 — intervention group
Group type: COMPARATOR
Intervention: Simulated KFC at 0 degrees
Number of subjects: 10
Study 1741999 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated KFC at 10 degrees
Number of subjects: 10
Study 1741999 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated KFC at 20 degrees
Number of subjects: 10
Study 1741999 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated KFC at 30 degrees
Number of subjects: 10
Study 1741999 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated KFC at 40 degrees
Number of subjects: 10
Study 6708116 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct training of spousal communication skills
Number of subjects: 0
Study 6708116 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of videotaped simulations of direct training
Number of subjects: 0
Study 6708116 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy with telephone contacts
Number of subjects: 0
Study 6708116 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 30964972 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Sonicare TongueCare+ BreathRx regimen (STC)
Number of subjects: 168
Study 30964972 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint antiseptic rinse (LCM)
Number of subjects: 168
Study 30964972 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue brushing with an ADA reference manual toothbrush (MTB)
Number of subjects: 168
Study 29777379 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based education
Number of subjects: 62
Study 29777379 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (non-video group)
Number of subjects: 62
Study 29777379 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (video and non-video)
Number of subjects: 62
Study 26633738 — intervention group
Group type: EXPERIMENTAL
Intervention: Shirodkar cerclage
Number of subjects: 98
Study 26633738 — intervention group
Group type: EXPERIMENTAL
Intervention: McDonald cerclage
Number of subjects: 98
Study 26633738 — intervention group
Group type: COMPARATOR
Intervention: Bedrest (no cerclage)
Number of subjects: 98
Study 24299553 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) containing 30 μg ethinyl estradiol and 3 mg drospirenone (group I; n = 21)
Number of subjects: 40
Study 24299553 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive vaginal ring (group II; n = 19)
Number of subjects: 40
Study 22764183 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 2128
Study 22764183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2128
Study 20154234 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory and Preventive Team Care (from family physicians, nurse practitioners, and a pharmacist)
Number of subjects: 241
Study 20154234 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 241
Study 18771993 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 327
Study 18771993 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 327
Study 15975313 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment with leeching intervention, n = 24
Number of subjects: 44
Study 15975313 — intervention group
Group type: COMPARATOR
Intervention: Conventional corticosteroid treated group (control group), n = 20
Number of subjects: 44
Study 15975313 — intervention group
Group type: COMPARATOR
Intervention: Comparison between leeching group and control group
Number of subjects: 44
Study 12669128 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation reactivation observed at the time of recurrence with increased plasma TAT levels.
Number of subjects: 113
Study 12669128 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation reactivation observed at the time of recurrence with increased plasma SF levels.
Number of subjects: 113
Study 12669128 — intervention group
Group type: EXPERIMENTAL
Intervention: F1+2 levels measured preoperatively and at recurrence.
Number of subjects: 113
Study 12669128 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative coagulation tests (F1+2, TAT, SF)
Number of subjects: 113
Study 10228510 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolytically detachable coils (coil embolization)
Number of subjects: 109
Study 10228510 — intervention group
Group type: COMPARATOR
Intervention: Surgical ligation
Number of subjects: 109
Study 10228510 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 109
Study 10228510 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 109
Study 10228510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 109
Study 8767565 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygroscopic HME (DAR Hygrobac S)
Number of subjects: 49
Study 8767565 — intervention group
Group type: COMPARATOR
Intervention: Heated humidifier (Fisher & Paykel MR 630 B)
Number of subjects: 49
Study 1702557 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous drainage of pancreatic abscesses
Number of subjects: 85
Study 1702557 — intervention group
Group type: COMPARATOR
Intervention: Surgical drainage of pancreatic abscesses
Number of subjects: 85
Study 1702557 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous drainage of infected pseudocysts
Number of subjects: 85
Study 1702557 — intervention group
Group type: COMPARATOR
Intervention: Surgical drainage of infected pseudocysts
Number of subjects: 85
Study 1702557 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous aspiration of noninfected pseudocysts
Number of subjects: 85
Study 1702557 — intervention group
Group type: COMPARATOR
Intervention: Surgical drainage of noninfected pseudocysts
Number of subjects: 85
Study 1702557 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous techniques
Number of subjects: 85
Study 31310183 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) tool
Number of subjects: 941
Study 29027235 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-based denoising techniques or iterative reconstruction algorithms
Number of subjects: 103
Study 29027235 — intervention group
Group type: COMPARATOR
Intervention: Commercially reconstructed quarter-dose images with no noise reduction
Number of subjects: 103
Study 29027235 — intervention group
Group type: COMPARATOR
Intervention: Full-dose commercial images
Number of subjects: 103
Study 25852024 — intervention group
Group type: EXPERIMENTAL
Intervention: GT3X
Number of subjects: 10
Study 25852024 — intervention group
Group type: EXPERIMENTAL
Intervention: Actiheart
Number of subjects: 10
Study 25852024 — intervention group
Group type: COMPARATOR
Intervention: ActivPAL
Number of subjects: 10
Study 23873853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 18 mg
Number of subjects: 667
Study 23873853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study 21571362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg/day
Number of subjects: 779
Study 21571362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 1197 mg/day
Number of subjects: 779
Study 21571362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 779
Study 19265735 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute HIV posttest educational video
Number of subjects: 128
Study 19265735 — intervention group
Group type: COMPARATOR
Intervention: Posttest educational session with an HIV counselor
Number of subjects: 128
Study 17546902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine monotherapy
Number of subjects: 0
Study 17546902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine monotherapy
Number of subjects: 0
Study 17546902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Chloroquine + Sulfadoxine/pyrimethamine)
Number of subjects: 0
Study 17546902 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 15497491 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 20
Study 15497491 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 20
Study 11686428 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg inhaled plus 200 microg intranasal budesonide once daily
Number of subjects: 21
Study 11686428 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg montelukast plus 10 mg cetirizine once daily
Number of subjects: 21
Study 11686428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9307671 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-channel antagonists
Number of subjects: 0
Study 9307671 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7947312 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral placement of the ventricular catheter
Number of subjects: 58
Study 7947312 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral placement of the ventricular catheter
Number of subjects: 58
Study 7947312 — intervention group
Group type: EXPERIMENTAL
Intervention: Special catheter with two sets of holes (contralateral placement)
Number of subjects: 58
Study 3145528 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine administration
Number of subjects: 0
Study 3145528 — intervention group
Group type: COMPARATOR
Intervention: Saline (control) administration
Number of subjects: 0
Study 31022003 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based and home-based exercise intervention
Number of subjects: 25
Study 31022003 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 25
Study 29073915 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube (LT)
Number of subjects: 78
Study 29073915 — intervention group
Group type: COMPARATOR
Intervention: Bag-valve-mask (BVM)
Number of subjects: 78
Study 26092818 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg once daily) plus trastuzumab and paclitaxel
Number of subjects: 719
Study 26092818 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and paclitaxel
Number of subjects: 719
Study 26092818 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg once daily)
Number of subjects: 719